A few previous studies have compared flortaucipir binding patterns with the patterns observed for other novel tau-PET radioligands in vivo in the same patients, including THK5351,411  18F-RO948412 and florquinitau (MK6240).413 Compared with THK5351, flortaucipir showed correlated, but higher, binding in Alzheimer’s disease patients and lower binding in FTD. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.